Search Results
Your search for where matches 5550 pages
Showing 2551 - 2600Young People Get Lung Cancer, Too
I’ve been in excellent physical shape my whole life. Growing up, it was my dream to play Division 1 soccer in college, and I trained hard throughout high school to achieve that goal. My dream came true, in 2005, when I was invited to play soccer at East Carolina University. I was eager to bond...
Preliminary Results Show Activity for Mesothelin‑Directed CAR T-Cell Therapy in Malignant Mesothelioma
A phase I clinical trial showed encouraging results with chimeric antigen receptor (CAR) T-cell therapy targeted to the mesothelin protein in patients with mesothelin-associated malignant pleural solid tumors—primarily, malignant mesothelioma—that had progressed following standard platinum-based...
Does Squamous Cell Carcinoma Risk Change With Immunosuppression?
Immunosuppressed patients seem to have an increased risk of poor outcomes with multiple squamous cell carcinomas compared with those who are immunocompetent. Jessica L. Gonzalez, MD, of Tufts Medical Center in Boston, and colleagues published the results of a single-center case-control study...
The Evolving Role of Pathologists in the Diagnosis and Treatment of Cancer
In the past, the role of the pathologist was primarily to present anatomic pathology findings on various specimens, particularly at tumor boards. However, in the emerging age of personalized medicine and molecular diagnostics, the responsibilities of pathologist have greatly expanded into...
Expert Point of View: Joseph Mikhael, MD
PRESS BRIEFING moderator Joseph Mikhael, MD, Professor of Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center in Phoenix, noted that traditional models are based on simplicity, and the scoring system contains few variables. “In an era...
House Calls With Her Physician Father Sparked an Interest in Palliative Care for Janet L. Abrahm, MD
Nationally regarded palliative care expert Janet L. Abrahm, MD, was born and reared in San Francisco. Her father was a solo practitioner who saw medicine as a great profession. “My father would come home from his office for dinner and when he finished, he’d do house calls, often bringing us with...
Colonoscopy Polyp Detection Rates and Endoscopist Characteristics
Previous research has suggested that specific factors about the doctor performing colonoscopy—for example, a gastroenterologist vs a surgeon, female vs male—were associated with different rates of detection of precancerous polyps. However, a Cleveland Clinic–led research team...
Shared Decision-Making in Lung Cancer Screening: Whence? Whither?
We read with interest a recent article published on ASCOPost.com, which summarized a paper on the role of shared decision-making in lung cancer screening.1,2 The summary and original report highlight a mandate by the Centers for Medicare & Medicaid Services (CMS) that bears careful...
NRG1 Gene Fusions Detected at Low Incidence Across Multiple Tumor Types
A consortium of researchers have completed an analysis of a new gene fusion they believe is responsible for the development of a wide spectrum of cancer types. According to the investigators, their studies show that errant gene fusions in neuregulin-1, or NRG1, which are present in about...
Collaborative Telerehabilitation in Patients With Advanced Cancer
Recent research suggests that remotely delivering rehabilitation services to patients with advanced cancer may improve their physical function, pain, and quality of life, while allowing them to spend less time in hospitals and nursing homes. These findings were published by Cheville et al in JAMA...
ASCO Announces New Task Force to Address Rural Cancer Care Gap
Yesterday at the National Press Club in Washington, DC, ASCO announced a new task force aimed at reducing disparities and improving outcomes for patients and survivors of cancer who live in rural communities. The new Rural Cancer Care Task Force will identify opportunities to close the care gap and ...
Carson Leslie Foundation Joins Forces With ASCO’s Conquer Cancer Foundation to Fight Medulloblastoma
Carson Leslie was a kind, popular, lively teen who loved sports and spending time with his family and friends. He was a devoted student at The Covenant School of Dallas, where he was quarterback on the school’s football team, and he was an active member of Grace Bible Church. He shared a special...
Better Techniques Coming to Breast Cancer Screening
BREAST CANCER SCREENING is no longer “just mammography” but involves a growing list of ever more sophisticated techniques that are improving detection, according to Elizabeth Morris, MD, Professor of Radiology, the Larry Norton Chair, and Chief of the Breast Imaging Service at Memorial Sloan...
Human Gene Therapy: Progress and Oversight
The early debate over the social and ethical implications of gene therapy led the National Institutes of Health (NIH) to establish the Recombinant DNA Advisory Committee in 1974. However, the risks of human gene therapies were largely unknown until 1999, when a patient died of a massive immune...
Photos From the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Arie S. Belldegrun, MD, FACS (right), receives the Keynote Award before delivering his lecture on “Progress in Cell Therapy: A Three-Decade Personal Journey.” Dr. Belldegrun is Surgical Director of the Genitourinary Oncology Department at the University of California, Los Angeles. The award was...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
NEW AGENTS for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
Nivolumab Combined With Ipilimumab Shows Activity in Prostate Cancer Subsets
In contrast with melanoma, lung cancer, and kidney cancer, immune checkpoint inhibitor therapy has been disappointing in prostate cancer thus far. Because of success in treating other tumor types, interest remains high in exploring the effect of immunotherapy with checkpoint inhibition in prostate...
Trends in Neoadjuvant Therapy for Resectable Pancreatic Cancer
SEVERAL STUDIES at the 2019 Gastrointestinal Cancers Symposium evaluated the benefits of neoadjuvant treatment in patients with pancreatic cancer—and in patients deemed fully resectable, not just “borderline” resectable.1-3 Although the standard of care for resectable pancreatic ductal...
CheckMate 650: Nivolumab and Ipilimumab in Metastatic, Castration-Resistant Prostate Cancer
SOME PATIENTS with metastatic prostate cancer may respond to a combination of immune checkpoint inhibitors after treatment with hormonal therapy and chemotherapy is not successful, according to early results from the phase II CheckMate 650 trial. Principal Investigator Padmanee Sharma, MD, PhD,...
Conference Highlights From the 2019 Gastrointestinal and Genitourinary Cancers Symposiums
THIS YEAR saw a huge turnout and a large number of scientific abstracts presented at both the 2019 Gastrointestinal (GI) Cancers Symposium, held on January 17–19, and the 2019 Genitourinary (GU) Cancers Symposium, held on February 14–16, both in San Francisco. The GU Cancers Symposium attracted...
Racial Disparities in Matched Volunteer Stem Cell Donors
Although the pool of registered bone marrow donors has increased in recent years, a new study suggests that most patients of southern European and non-European descent are unlikely to have a suitable match if they need a bone marrow transplant. If an immediate registry search does not identify a...
FDA Pipeline: Mammography Policies, Designations for Leukemias and Myelodysplastic Syndrome
This week, the U.S. Food and Drug Administration (FDA) announced policy changes to modernize mammography policies and issued a Breakthrough Therapy designation, an Orphan Drug designation, and an investigational new drug application. FDA Advances Policy Changes to Modernize Mammography Services...
ASCO Weighs in on Widespread Youth Tobacco Use: See the Latest National Youth Tobacco Survey Results
APPROXIMATELY 5 MILLION middle and high school students reported currently using a tobacco product, with over 3.6 million currently using e-cigarettes and about 2.5 million currently using a combustible tobacco product, according to the latest findings from the National Youth Tobacco Survey ...
New ASCO Guideline Makes Safe Handling of Hazardous Drugs a Priority
ASCO HAS PUBLISHED a new guideline, “Safe Handling of Hazardous Drugs: ASCO Standards,” to promote the safety of pharmacists, nurses, and all staff who handle potentially dangerous medicines, such as chemotherapy compounds.1 Safety is pivotal in the entire drug workflow, including drug mixing and...
ASCO Endorses Active Surveillance Guideline for Low-Risk Prostate Cancer
ASCO ENDORSES and reinforces the evidence-based American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) Guideline published in 2018 in the Journal of Urology. ASCO’s endorsement of a guideline on clinically localized...
NCCN Summit Tackles Inequities in Access to Care
WHEN BRANDON CANYON’S mother Leone was diagnosed with uterine cancer, he drove her to treatment sessions at the nearest cancer center—a 200-mile round trip on rough roads. Gas was a significant expense, but their only other option was to forgo treatment. The Canyons are members of the Navajo...
Genomic Testing Associated With Lower Health-Care Costs in Patients With High-Risk Breast Cancer
New research published by Dinan et al in JNCCN—Journal of the National Comprehensive Cancer Network provides evidence that genomic recurrence score testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast...
Knowing Gender Identity and Sexual Orientation of Patients Is a Vital Aspect of Medical Care
A survey of oncologists from National Cancer Institute (NCI)-designated Comprehensive Cancer Centers found that 95.3% of oncologists who responded are comfortable with treating lesbian, gay, and bisexual patients with cancer, and 82.5% are comfortable treating transgender patients with cancer.1...
New England Cancer Specialists to Join Dana-Farber Cancer Care Collaborative
The Dana-Farber Cancer Institute announced recently that New England Cancer Specialists is the newest member of the Dana-Farber Cancer Care Collaborative. Participation in the Collaborative reflects a demonstrated commitment to excellence by meeting a wide array of standards and best practices....
Royal Swedish Academy of Sciences Accepting Candidates for Sjöberg Prize 2020
The Royal Swedish Academy of Sciences is accepting candidate nominations for The Sjöberg Prize 2020. The Sjöberg Prize for Cancer Research is awarded to scientists who have made major contributions to our knowledge about disease mechanisms, risk factors, or the treatment or prevention of cancer....
SGO 2019: HPV Vaccine Uptake in the Deep South
A study by Pierce et al presented at the Society of Gynecologic Oncology’s (SGO) 50th Annual Meeting on Women’s Cancer showed that human papillomavirus (HPV) vaccination rates in Alabama are highest in counties with high incidence rates of HPV-related cancer (Abstract 13). ...
The Risks of Drug Approval Based on Shaky Evidence
Two recent publications in The New England Journal of Medicine (NEJM), and the resulting drug approval applications that have already been filed, lead to concern that the basis of medical practice on valid evidence may be corrupted. Each involves statistically shaky analysis leading to a striking...
ASCO President-Elect Howard A. Burris III, MD, FACP, FASCO, Gained Leadership Skills From His Experience at West Point
GUEST EDITOR Dr. Abraham is the Director of the Breast Oncology Program at Taussig Cancer Institute, and Professor of Medicine, Lerner College of Medicine, Cleveland Clinic. In this installment of Living a Full Life, guest editor Jame Abraham, MD, spoke with Howard A. “Skip” Burris III, MD, FACP,...
CAR T-Cell Therapy for DLBCL: At the Crossroads of Hype and Reality
In the 20-plus years I have spent in hematologic oncology, I have been fortunate to have a ringside seat to watch “game-changing” advances come into our field—all-trans retinoic acid for acute promyelocytic leukemia, tyrosine kinase inhibitors starting with imatinib for chronic myeloid leukemia,...
EAU 2019: Testosterone Replacement Therapy May Slow Recurrence in Low-Risk Prostate Cancer
Researchers have shown that testosterone replacement may slow the recurrence of prostate cancer in low-risk patients. Findings from the study were presented by Towe et al at the European Association of Urology (EAU) 2019 Congress (Abstract 646). Practitioners have long regarded testosterone as a...
Fred R. Hirsch, MD, PhD, Named Executive Director of New Center for Thoracic Oncology at Mount Sinai
Fred R. Hirsch, MD, PhD, an authority on lung cancer treatment and research, has joined Mount Sinai Health System as Executive Director of the newly created Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai and will also serve as the Richard M. Stein, MD, Joe Lowe, and...
FDA Pipeline: Assay Approval, Breakthrough Designations for AI Technology and CLL, and More
In the past week, the U.S. Food and Drug Administration (FDA) approved a companion diagnostic assay, granted Breakthrough Device and Breakthrough Therapy designations, and extended the review period of a proposed treatment. The agency also published four draft guidances and one final guidance...
ASCO Honors Leaders in Cancer Care With 2019 Special Awards
ASCO and ASCO’s Conquer Cancer Foundation proudly recognize the winners of ASCO’s Special Awards, the Society's highest honors, and Conquer Cancer's Women Who Conquer Cancer Mentorship Awards. The recipients of these awards have worked to transform cancer care around the world. ASCO...
Global Incidence of Undiagnosed Pediatric Cancers
Nearly half of all childhood cancers are not being diagnosed globally, according to a new modeling study published by Ward et al in The Lancet Oncology. “Our model suggests that nearly one in two children with cancer are never diagnosed and may die untreated,” said lead...
A Peaceful Transformation: The Origin of the Frederick National Laboratory
JUST 2 MONTHS before Congress passed what to this day is America’s most sweeping anticancer legislation, President Richard Nixon came to Fort Detrick in Frederick, Maryland, to declare his administration’s historic commitment to the fight. “I have come here today for the purpose of making an...
Roy L. Silverstein, MD, Begins Term as 2019 ASH President
ROY L. SILVERSTEIN, MD, an expert in platelet and vascular cell biology, as well as clinical nonmalignant hematology and thrombosis, will serve as President of the American Society of Hematology (ASH) for a 1-year term through December 2019. Dr. Silverstein is Chairman of the Department of...
Although Evidence Is Clear That Lung Cancer Screening Saves Lives, Adoption Rates Remain Low
The findings of the National Lung Screening Trial (NLST), reported in 2011, revealed that participants who received low-dose helical computed tomography (CT) scans had a 20% lower risk of dying of lung cancer than participants who received standard chest x-rays. Despite these results,...
2019 AAD: Disadvantages and Potential Improvements of Artificial Intelligence in Skin Cancer Detection
While artificial intelligence (AI) systems for skin cancer detection have shown promise in research settings, there is still a lot of work to be done before the technology is appropriate for real-world use. This was the topic of a scientific session at the 2019 American Academy of Dermatology (AAD) ...
Eliminating the Taboo of Cancer
All homes and all families have or have had their own cancer experiences. Speaking about it dissolves the taboo and allows for earlier diagnosis, less discrimination, increased awareness, and higher commitment by authorities. It also helps those struggling with the disease feel like part of a...
Who I Am and What I Will Do
I am a radiation oncologist from Zambia, where we only have one cancer center offering radiotherapy—and I will beat cancer. This bold statement often evokes a look of surprise. However, if the conversation is allowed to go on, I’ll say cancer is beatable even where resources are thin. I am...
Cancer Drug Development Award Given to Geoffrey Shapiro, PhD, MD
The Targeted Anticancer Therapies (TAT) 2019 Honorary Award for cancer drug development has been given to Geoffrey Shapiro, PhD, MD, Professor of Medicine at Harvard Medical School and institute physician at the Dana-Farber Cancer Institute (DFCI), for his leadership in developmental therapeutics. ...
Advances in Haploidentical Transplantation and Cellular Therapies
With advances in the field, the number of haploidentical stem cell transplants being performed (ie, using human leukocyte antigen [HLA] half-matched donor stem cells) has been increasing. In recognition of evolving strategies to improve outcomes, a group of transplant physicians started the...
Neoadjuvant Palbociclib Plus Letrozole Reduces Ki67 Levels
In the neoadjuvant setting, adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation, as measured by Ki67 levels, in patients with primary estrogen receptor–positive breast cancer but did not increase the clinical response rate over 14 weeks, according ...
Long-Term Study Finds Axillary Radiotherapy Safe and Effective After Positive Sentinel Node Biopsy
Following identification of a positive sentinel lymph node, surgical axillary lymph node dissection and axillary radiation therapy provide comparable locoregional control and survival, according to a 10-year follow-up of the large European Organisation for Research and Treatment of Cancer AMAROS...
Expert Point of View: Robert Dreicer, MD, MS, MACP, FASCO, and Sumanta K. Pal, MD
“This is an intriguing agent,” said ASCO expert Robert Dreicer, MD, MS, MACP, FASCO, of the University of Virginia Cancer Center and moderator of a press briefing where these data were discussed. “Survival rates are low for patients with metastatic castration--resistant prostate cancer, and the...
